Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28
about
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesCancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomasIdentification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patientsCT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis.Expression of cancer/testis antigens in cutaneous T cell lymphomas.A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia.The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner.CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis.NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.Cancer/testis antigens: structural and immunobiological properties.Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cellsMonitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.Rapid generation of NY-ESO-1-specific CD4(+) THELPER1 cells for adoptive T-cell therapy.Toxicities Associated With Adoptive T-Cell Transfer for Cancer.Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinomaDirections in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Use of autoantibodies in breast cancer screening and diagnosis.NY-ESO-1 immunotherapy for multiple myeloma.Immunotherapeutic strategies for high-risk bladder cancer.Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease.LDH-C4: a target with therapeutic potential for cancer and contraception.Current status and future prospects of peptide-based cancer vaccines.New paths in human cancer serology.Expression and immunogenicity of NY-ESO-1 in colorectal cancer.A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma.Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.[Expression and Clinical Significance of MAGE-C2 in Lung Adenocarcinoma].
P2860
Q28188712-1CA5822F-CB36-41AD-88F3-FFF00A98E117Q28220657-92D294EB-A9CD-4154-875B-E6803436D107Q28975750-0D75642D-1F49-4F4F-9D83-541CA049555FQ30829189-FA715541-1187-48B0-A912-DDF09B5C46C6Q31036179-57040ABA-B568-4A20-8B2F-D10AFBF25C9AQ33709910-85DB3153-9D75-4F81-8695-C51E98CF3217Q33825170-F58702B1-E42C-47F3-86D3-018612F8963FQ33892059-406A5AA9-1062-4BA8-8682-C05AD6B87D91Q34221846-C3F9C29A-3B00-4A53-9129-A13B28205B58Q34568997-A20303D2-7709-4842-883D-2134E299DFF0Q34795079-90541D91-3086-405E-B3E4-936F999A09BDQ35067995-D627D875-8177-49E6-BEF1-5DA98FC5BE2DQ35693584-28FD8091-5F10-43E7-AEBB-96B335093A94Q35733359-78135D1B-79EB-48BB-B6D8-02B8124A5A8FQ35799353-0B422BF3-D5F7-42AC-A0AD-0FF9DF6036F5Q36307671-34404CAD-BF10-41F7-BD9B-8AF5D9FE6510Q36400401-B992FEED-E8C1-450A-9B91-710E283FE4CAQ36471827-3D16C83A-C6BD-48DA-B467-761D39C032BBQ36573831-30DA52D0-538B-4701-8E0F-8C2C7E9E51F9Q36637651-2D2959B6-B11F-42ED-8C2B-D864B5485C28Q36768976-6911DB54-7A8E-40DB-9B63-7E640FE3324BQ37136357-241D43D7-FD2A-47CB-AAAB-F758E2C52B4CQ37635491-14D912D2-AB10-4310-A058-6AB6A825E1EAQ37788829-261386BF-4FF6-4BC4-BFF7-605E004364D0Q38034661-45CE7F53-5DD3-4731-9252-BD54D8AFA2E7Q38780728-4F6E234E-1E1C-49E1-9CFF-2839B2117DEAQ41821668-6E8CB9C5-6E4A-43F1-9FB0-B4902E7E556CQ42235384-55904D77-3575-4AEF-9E4C-C0692CC99301Q42505471-8A4638F0-BDAF-445C-A3AB-2EA0433449BFQ47132018-CFB989E9-ED6D-4F6B-AB53-DD5431E7F2F2Q50769076-2CE5ED49-DD7C-4E01-8F1B-136D479FFEB9Q51061495-48506CF2-5BA5-46E9-9371-998D87E9AEA6Q55447676-AB32FC63-843A-4FE6-8005-D9D0C108D5CE
P2860
Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28
description
1997 nî lūn-bûn
@nan
1997 թուականին հրատարակուած գիտական յօդուած
@hyw
1997 թվականին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@ast
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@en
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@nl
type
label
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@ast
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@en
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@nl
prefLabel
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@ast
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@en
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@nl
P2093
P356
P1476
Genomic cloning and localizati ...... SO-1, to human chromosome Xq28
@en
P2093
P304
P356
10.1159/000134734
P407
P577
1997-01-01T00:00:00Z